Limits...
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J - Leuk Res Rep (2015)

Bottom Line: We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP.Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse.Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

View Article: PubMed Central - PubMed

Affiliation: Hematology, Hospital Arnau de Vilanova, Valencia, Spain.

ABSTRACT
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

No MeSH data available.


Related in: MedlinePlus

Post relapse progression-free survival according to front-line treatment (A) and (B) progression-free survival depending on the type of therapy administered at relapse.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588395&req=5

f0010: Post relapse progression-free survival according to front-line treatment (A) and (B) progression-free survival depending on the type of therapy administered at relapse.

Mentions: The median follow-up from the time of disease relapse or progression was 14.3 months and 136 patients (94%) have progressed or died after relapse. The median PFS after relapse in the overall series was 8.84 (95% confidence interval [CI]: 6.37–11.53) months and it was 9.92 (95% CI: 7.36–14.7) and 8.49 (95% CI: 4.96–11.5) months among patients receiving induction with VMP and VTP, respectively (Fig. 2A). According to maintenance therapy, PFS was 8.5 and 8.9 months among patients receiving VP or VT and 8.7 months in those patients who did not receive maintenance (P non significant). Median PFS was, 11.73 (95% CI: 4.24–17), 8.84 (95% CI: 6.18–15.3), and 7.90 (95% CI: 3.15–12.5) for patients receiving bortezomib-, lenalidomide-, and chemotherapy-based therapies at time of relapse, respectively (Fig. 2B). No significant differences were observed in PFS among patients in the VMP and VTP groups according to the type of therapy administered at relapse (data not shown).


Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J - Leuk Res Rep (2015)

Post relapse progression-free survival according to front-line treatment (A) and (B) progression-free survival depending on the type of therapy administered at relapse.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588395&req=5

f0010: Post relapse progression-free survival according to front-line treatment (A) and (B) progression-free survival depending on the type of therapy administered at relapse.
Mentions: The median follow-up from the time of disease relapse or progression was 14.3 months and 136 patients (94%) have progressed or died after relapse. The median PFS after relapse in the overall series was 8.84 (95% confidence interval [CI]: 6.37–11.53) months and it was 9.92 (95% CI: 7.36–14.7) and 8.49 (95% CI: 4.96–11.5) months among patients receiving induction with VMP and VTP, respectively (Fig. 2A). According to maintenance therapy, PFS was 8.5 and 8.9 months among patients receiving VP or VT and 8.7 months in those patients who did not receive maintenance (P non significant). Median PFS was, 11.73 (95% CI: 4.24–17), 8.84 (95% CI: 6.18–15.3), and 7.90 (95% CI: 3.15–12.5) for patients receiving bortezomib-, lenalidomide-, and chemotherapy-based therapies at time of relapse, respectively (Fig. 2B). No significant differences were observed in PFS among patients in the VMP and VTP groups according to the type of therapy administered at relapse (data not shown).

Bottom Line: We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP.Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse.Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

View Article: PubMed Central - PubMed

Affiliation: Hematology, Hospital Arnau de Vilanova, Valencia, Spain.

ABSTRACT
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

No MeSH data available.


Related in: MedlinePlus